Nuclear Medicine And Biology SCIE
國際簡稱：NUCL MED BIOL 參考譯名：核醫學與生物學
主要研究方向：醫學-核醫學 非預警期刊 審稿周期： 一般,3-8周 約8周
《核醫學與生物學》(Nuclear Medicine And Biology)是一本由Elsevier Inc.出版的以醫學-核醫學為研究特色的國際期刊，發表該領域相關的原創研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發現，旨在促進該學科領域科學信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預警名單。
- 4區 中科院分區
- Q1 JCR分區
- 38 年發文量
- 3.6 IF影響因子
- 未開放 是否OA
- 82 H-index
- 1993 創刊年份
- Bimonthly 出版周期
- Multi-Language 出版語言
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
Nuclear Medicine And Biology歷年數據統計
影響因子
中科院分區
Nuclear Medicine And Biology中國學者發文選摘
-
1、A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
Author: Yu Tang, Yingjiang Hu, Weihao Liu, Lin Chen, Yan Zhao, Huan Ma, Jijun Yang, Yuanyou Yang, Jiali Liao, Jiming Cai, Yue Chen, Ning Liu
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2019, Vol.70, 23-31, DOI:10.1016/j.nucmedbio.2019.01.007
-
2、In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model
Author: Honglei Jiao, Xinming Zhao, Jiahui Liu, Tuo Ma, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2018, Vol., , DOI:10.1016/j.nucmedbio.2018.11.004
-
3、Radiosynthesis and biological evaluation of N-(2-[18F]fluoropropionyl)-3,4-dihydroxy-l-phenylalanine as a PET tracer for oncologic imaging
Author: Caihua Tang, Dahong Nie, Ganghua Tang, Siyuan Gao, Shaoyu Liu, Fuhua Wen, Xiaolan Tang
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.50, 39-46, DOI:10.1016/j.nucmedbio.2017.04.002
-
4、99mTc-3PRGD2 scintigraphy to stage liver fibrosis and evaluate reversal after fibrotic stimulus withdrawn
Author: Xin Zhang, Qiyong Guo, Yu Shi, Weina Xu, Shupeng Yu, Zhiguang Yang, Li Cao, Changping Liu, Zhoushe Zhao, Jun Xin
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 44-49, DOI:10.1016/j.nucmedbio.2017.02.004
-
5、Simple and rapid radiosynthesis of N-18F-labeled glutamic acid as a hepatocellular carcinoma PET tracer
Author: Aixia Sun, Shaoyu Liu, Xiaolan Tang, Dahong Nie, Ganghua Tang, Zhanwen Zhang, Fuhua Wen, Xiaoyan Wang
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 38-43, DOI:10.1016/j.nucmedbio.2017.02.003
-
6、Effect of methoxy group position on biological properties of 18F–labeled benzyl triphenylphosphonium cations
Author: Shuting Chen, Zuoquan Zhao, Ying Zhang, Wei Fang, Jie Lu, Xianzhong Zhang
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 16-23, DOI:10.1016/j.nucmedbio.2017.02.002
-
7、Gefitinib enhances radiotherapeutic effects of 131I–hEGF targeted to EGFR by increasing tumor uptake of hEGF in tumor xenografts
Author: Lu Xia, He Peng, Luo Zhiqiang, Zhang Xiaoli
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 63-68, DOI:10.1016/j.nucmedbio.2017.01.013
-
8、99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
Author: Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Jingyi Cheng, Yingjian Zhang
Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 69-75, DOI:10.1016/j.nucmedbio.2017.01.010
Nuclear Medicine And Biology同類期刊
-
公共衛生前沿
Frontiers In Public Health
中科院 3區 JCR Q2
-
藥理學前沿
Frontiers In Pharmacology
中科院 2區 JCR Q1
-
生物醫學與藥物治療
Biomedicine & Pharmacotherapy
中科院 2區 JCR Q1
-
探索腫瘤學
Discover Oncology
中科院 4區 JCR Q2
-
Bmc精神病學
Bmc Psychiatry
中科院 2區 JCR Q2
-
Bmc神經病學
Bmc Neurology
中科院 3區 JCR Q3
-
材料化學雜志 B
Journal Of Materials Chemistry B
中科院 3區 JCR Q1
-
美康
Medcomm
中科院 3區 JCR Q1
免責聲明
若用戶需要出版服務，請聯系出版商：ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710。